Drugs / EBV-specific TCR-T cell with anti-PD1 auto-secreted element
EBV-specific TCR-T cell with anti-PD1 auto-secreted element
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04139057 | Mar 2019 → Jan 2026 | head and neck squamous cell carcinoma | Xinqiao Hospital of Chongqing | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV-specific TCR-T cell with anti-PD1 auto-secreted element | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04139057 ↗ |
| Action | Inhibit | “TCR-T cells armed with a PD1 antagonist could further enhance the efficacy of TCR-T in solid cancers.” NCT04139057 ↗ |
| Modality | Cell therapy | “Engineered T cells bearing a TCR (TCR-T) that can specifically recognize the presented EBV antigen become a viable approach to treat this type of cancer.” NCT04139057 ↗ |